Literature DB >> 18509038

Cellular and behavioral interactions of gabapentin with alcohol dependence.

Marisa Roberto1, Nicholas W Gilpin, Laura E O'Dell, Maureen T Cruz, Andrew C Morse, George R Siggins, George F Koob.   

Abstract

Gabapentin is a structural analog of GABA that has anticonvulsant properties. Despite the therapeutic efficacy of gabapentin, its molecular and cellular mechanisms of action are unclear. The GABAergic system in the central nucleus of the amygdala (CeA) plays an important role in regulating voluntary ethanol intake. Here, we investigated the effect of gabapentin on GABAergic transmission in CeA slices, on ethanol intake, and on an anxiety measure using animal models of ethanol dependence. Gabapentin increased the amplitudes of evoked GABA receptor-mediated IPSCs (GABA-IPSCs) in CeA neurons from nondependent rats, but decreased their amplitudes in CeA of ethanol-dependent rats. Gabapentin effects were blocked in the presence of a specific GABA(B) receptor antagonist. The sensitivity of the GABA-IPSCs to a GABA(B) receptor antagonist and an agonist was decreased after chronic ethanol, suggesting that ethanol-induced neuroadaptations of GABA(B) receptors associated with ethanol dependence may account for the differential effects of gabapentin after chronic ethanol. Systemic gabapentin reduced ethanol intake in dependent, but not in nondependent, rats and reversed the anxiogenic-like effects of ethanol abstinence using an acute dependence model. Gabapentin infused directly into the CeA also blocked dependence-induced elevation in operant ethanol responding. Collectively, these findings show that gabapentin reverses behavioral measures of ethanol dependence and, in turn, dependence reverses the effects of gabapentin on CeA neurons, and suggest that gabapentin represents a potential medication for treatment of alcoholism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509038      PMCID: PMC2493536          DOI: 10.1523/JNEUROSCI.0575-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  68 in total

1.  Ethanol and sucrose seeking and consumption following repeated administration of the GABA(B) agonist baclofen in rats.

Authors:  Cristine L Czachowski; Brooke H Legg; Kirstie H Stansfield
Journal:  Alcohol Clin Exp Res       Date:  2006-05       Impact factor: 3.455

Review 2.  The mechanisms of action of gabapentin and pregabalin.

Authors:  Graeme J Sills
Journal:  Curr Opin Pharmacol       Date:  2005-12-22       Impact factor: 5.547

3.  Ethanol enhances gamma-aminobutyric acid responses in a subpopulation of nucleus accumbens neurons: role of metabotropic glutamate receptors.

Authors:  Z Nie; S G Madamba; G R Siggins
Journal:  J Pharmacol Exp Ther       Date:  2000-05       Impact factor: 4.030

4.  Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanol-induced increase of GABA release in central amygdala.

Authors:  Marisa Roberto; George R Siggins
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-20       Impact factor: 11.205

5.  Effects of gabapentin on spontaneous discharges and subthreshold membrane potential oscillation of type A neurons in injured DRG.

Authors:  Rui-Hua Yang; Jun-Ling Xing; Jian-Hong Duan; San-Jue Hu
Journal:  Pain       Date:  2005-08       Impact factor: 6.961

6.  Abecarnil and alprazolam reverse anxiety-like behaviors induced by ethanol withdrawal.

Authors:  M E Jung; C J Wallis; M B Gatch; H Lal
Journal:  Alcohol       Date:  2000-06       Impact factor: 2.405

7.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

8.  A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal.

Authors:  John J Mariani; Richard N Rosenthal; Susan Tross; Prameet Singh; Om P Anand
Journal:  Am J Addict       Date:  2006 Jan-Feb

9.  Differential G-protein coupling to GABAB receptor in limbic areas of alcohol-preferring and -nonpreferring rats.

Authors:  M Paola Castelli; Fabio Pibiri; A Paola Piras; Giovanni Carboni; Alessandro Orrù; Gian Luigi Gessa; Mauro A M Carai; Giancarlo Colombo
Journal:  Eur J Pharmacol       Date:  2005-10-13       Impact factor: 4.432

10.  Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices.

Authors:  K Fink; W Meder; D J Dooley; M Göthert
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

View more
  62 in total

Review 1.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

2.  Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Michael J Wesley; Thomas H Kelly; Lon R Hays
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

3.  Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.

Authors:  Daniel E Falk; Megan L Ryan; Joanne B Fertig; Eric G Devine; Ricardo Cruz; E Sherwood Brown; Heather Burns; Ihsan M Salloum; D Jeffrey Newport; John Mendelson; Gantt Galloway; Kyle Kampman; Catherine Brooks; Alan I Green; Mary F Brunette; Richard N Rosenthal; Kelly E Dunn; Eric C Strain; Lara Ray; Steven Shoptaw; Nassima Ait-Daoud Tiouririne; Erik W Gunderson; Janet Ransom; Charles Scott; Lorenzo Leggio; Steven Caras; Barbara J Mason; Raye Z Litten
Journal:  Alcohol Clin Exp Res       Date:  2018-12-09       Impact factor: 3.455

4.  Altered gamma-aminobutyric acid type B receptor subunit 1 splicing in alcoholics.

Authors:  Changhoon Lee; R Dayne Mayfield; R Adron Harris
Journal:  Biol Psychiatry       Date:  2013-10-24       Impact factor: 13.382

5.  Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat.

Authors:  Serena Stopponi; Lorenzo Somaini; Andrea Cippitelli; Giordano de Guglielmo; Marsida Kallupi; Nazzareno Cannella; Gilberto Gerra; Maurizio Massi; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-02       Impact factor: 4.530

Review 6.  An Animal Model of Alcohol Dependence to Screen Medications for Treating Alcoholism.

Authors:  H C Becker; M F Lopez
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

Review 7.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

8.  Novel anticonvulsants for reducing alcohol consumption: A review of evidence from preclinical rodent drinking models.

Authors:  A E Padula; N S McGuier; W C Griffin; M F Lopez; H C Becker; P J Mulholland
Journal:  OA Alcohol       Date:  2013-02-01

9.  Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin.

Authors:  Barbara J Mason; John M Light; Lauren D Williams; David J Drobes
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

10.  The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking.

Authors:  Valentina Sabino; Pietro Cottone; Yu Zhao; Malliga R Iyer; Luca Steardo; Luca Steardo; Kenner C Rice; Bruno Conti; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.